DIM
TCRX icon

DC Investments Management’s TScan Therapeutics TCRX Stock Holding History

DC Investments Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.9K Hold
35,563
– – 0.01% 76
2025
Q4 		$35.6K Hold
35,563
– – 0.02% 48
2025
Q3 		$64.7K Hold
35,563
– – 0.03% 95
2025
Q2 		$51.6K Hold
35,563
– – 0.02% 104
2025
Q1 		$49.1K Hold
35,563
– – 0.03% 110
2024
Q4 		$108K Hold
35,563
– – 0.07% 89
2024
Q3 		$177K Hold
35,563
– – 0.12% 84
2024
Q2 		$208K Hold
35,563
– – 0.18% 80
2024
Q1 		$282K Hold
35,563
– – 0.23% 84
2023
Q4 		$207K Hold
35,563
– – 0.21% 73
2023
Q3 		$91K Hold
35,563
– – 0.11% 83
2023
Q2 		$88.9K Hold
35,563
– – 0.1% 81
2023
Q1 		$74.7K Hold
35,563
– – 0.09% 82
2022
Q4 		$55.1K Hold
35,563
– – 0.07% 58
2022
Q3 		$110K Hold
35,563
– – 0.25% 27
2022
Q2 		$112K Hold
35,563
– – 0.25% 36
2022
Q1 		$100K Hold
35,563
– – 0.17% 46
2021
Q4 		$160K Hold
35,563
– – 0.23% 54
2021
Q3 		$297K Buy
+35,563
New +$330K 0.55% 41

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

DC Investments Management's TCRX Position: Q1 2026 in Review

DC Investments Management held its TScan Therapeutics (TCRX) position steady in Q1 2026 at 35,563 shares worth $35.9K. The position accounts for 0.01% of the portfolio, ranked #76.

DC Investments Management first reported a position in TCRX in Q3 2021 and has held it in 19 quarters since. The position peaked at $297K in Q3 2021. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • DC Investments Management held 35,563 shares of TScan Therapeutics worth $35.9K as of Q1 2026.
  • DC Investments Management left its TScan Therapeutics share count unchanged in Q1 2026.
  • TScan Therapeutics made up 0.01% of DC Investments Management's portfolio in Q1 2026, its #76 holding.
  • DC Investments Management first reported a position in TScan Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • DC Investments Management's TScan Therapeutics position peaked at $297K in Q3 2021.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on DC Investments Management's 13F filing for Q1 2026, filed 14 May 2026.